TY - JOUR AU - Ali, Dr Syed Salman AU - Shaukat, Javeria AU - Ahmed, Rabia AU - Muhammad, Iqbal PY - 2018/08/31 Y2 - 2024/03/28 TI - IMMUNOHISTOCHEMICAL EXPRESSION OF GLYPICAN-3 IN HEPATOCELLULAR CARCINOMA: Glypican-3 in Hepatocellular Carcinoma JF - Pakistan Armed Forces Medical Journal JA - PAFMJ VL - 68 IS - 4 SE - Original Articles DO - UR - https://pafmj.org/PAFMJ/article/view/5 SP - 692-96 AB - <p><strong>Objective</strong>: To determine the frequency of immunohistochemically expression of Glypican-3 in hepatocellular carcinoma on liver biopsies.<br><strong>Study Design:</strong> Descriptive cross-sectional study.<br><strong>Place and Duration of Study:</strong> Department of Histopathology, Armed Forces Institute of Pathology (AFIP),&nbsp;Rawalpindi, from Jun 2015 to Jun 2016.<br><strong>Material and Methods:</strong> A total of 55 liver biopsies from the patients of hepatocellular carcinoma were included in&nbsp;the study. Age, gender, tumor grade and immunohistochemically expression of glypican-3 were noted. The data&nbsp;were analyzed by SPSS version 21. Mean and SD were calculated for numerical variables such as age. Percentages&nbsp;and frequencies were calculated for gender, tumor grade and immunohistochemically expression of glypican-3.&nbsp;The data collected for study were statistically analyzed using chi-square test.<br><strong>Results:</strong> Out of 55 patients of hepatocellular carcinoma, 44 (80%) were males and 11 (20%) were females. The age&nbsp;of the patients was between 41 and 80 years with an average age of 59.7 years and standard deviation of ± 8.8.&nbsp;Out of 55 cases, 32 cases (58.2%) were well differentiated, 18 cases (32.7%) were moderately differentiated and&nbsp;5 cases (9.1%) were poorly differentiated. Forty-eight cases of hepatocellular carcinoma (87.3%) showed positivity&nbsp;for glypican-3 while 7 cases (12.7%) were negative. A significant statistical association was not seen among age,&nbsp;gender, tumor grade and glypican-3 expression, p-value being &gt;0.05.<br><strong>Conclusion:</strong> The high expression of glypican-3 in hepatocellular carcinoma suggests its diagnostic utility and&nbsp;also its value in distinguishing hepatocellular carcinoma from other hepatic lesions. As antiglypican-3 therapy is&nbsp;currently under clinical evaluation, it might be useful as a therapeutic target in glypican-3 positive hepatocellular&nbsp;carcinoma cases.</p> ER -